Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomized, open‐label, treat‐to‐target non‐inferiority trial

M. J. Davies; J. L. Gross; Y. Ono; T. Sasaki; G. Bantwal; M. A. Gall; M. Niemeyer; H. Seino;

doi:10.1111/dom.12298

Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomized, open‐label, treat‐to‐target non‐inferiority trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12298 ◽

2014 ◽

Vol 16 (10) ◽

pp. 922-930 ◽

Cited By ~ 29

Author(s):

M. J. Davies ◽

J. L. Gross ◽

Y. Ono ◽

T. Sasaki ◽

G. Bantwal ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Open Label ◽

Mealtime Insulin ◽

Basal Bolus

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(12)60204-9 ◽

2012 ◽

Vol 379 (9825) ◽

pp. 1489-1497 ◽

Cited By ~ 221

Author(s):

Simon Heller ◽

John Buse ◽

Miles Fisher ◽

Satish Garg ◽

Michel Marre ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Open Label ◽

Phase 3 ◽

Mealtime Insulin ◽

Basal Bolus

Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial

Clinical Therapeutics ◽

10.1016/j.clinthera.2009.10.006 ◽

2009 ◽

Vol 31 (10) ◽

pp. 2086-2097 ◽

Cited By ~ 60

Author(s):

Simon Heller ◽

Christoph Koenen ◽

Bruce Bode

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Insulin Detemir ◽

Treat To Target ◽

Open Label ◽

Parallel Group ◽

Mealtime Insulin ◽

Basal Bolus

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

Diabetes Care ◽

10.2337/dc11-2503 ◽

2012 ◽

Vol 35 (11) ◽

pp. 2174-2181 ◽

Cited By ~ 49

Author(s):

I. B. Hirsch ◽

B. Bode ◽

J.-P. Courreges ◽

P. Dykiel ◽

E. Franek ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Target Trial ◽

Open Label ◽

Phase 3 ◽

Once Daily ◽

Basal Bolus

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)

Diabetic Medicine ◽

10.1111/dme.13068 ◽

2016 ◽

Vol 34 (2) ◽

pp. 167-173 ◽

Cited By ~ 16

Author(s):

I. B. Hirsch ◽

E. Franek ◽

H. Mersebach ◽

L. Bardtrum ◽

K. Hermansen

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Randomized Clinical Trial ◽

Insulin Aspart ◽

Insulin Degludec ◽

Safety And Efficacy ◽

Mealtime Insulin ◽

Basal Bolus

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

Diabetic Medicine ◽

10.1111/dme.12243 ◽

2013 ◽

Vol 30 (11) ◽

pp. 1293-1297 ◽

Cited By ~ 65

Author(s):

B. W. Bode ◽

J. B. Buse ◽

M. Fisher ◽

S. K. Garg ◽

M. Marre ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Glycaemic Control ◽

Insulin Glargine ◽

Insulin Aspart ◽

Insulin Degludec ◽

Nocturnal Hypoglycaemia ◽

Mealtime Insulin ◽

Basal Bolus

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(12)60205-0 ◽

2012 ◽

Vol 379 (9825) ◽

pp. 1498-1507 ◽

Cited By ~ 212

Author(s):

Alan J Garber ◽

Allen B King ◽

Stefano Del Prato ◽

Seamus Sreenan ◽

Mustafa K Balci ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Open Label ◽

Phase 3 ◽

Mealtime Insulin ◽

Basal Bolus

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)

Diabetes Care ◽

10.2337/dc08-0332 ◽

2008 ◽

Vol 32 (1) ◽

pp. 32-37 ◽

Cited By ~ 33

Author(s):

J.-P. Le Floch ◽

M. Levy ◽

H. Mosnier-Pudar ◽

F. Nobels ◽

S. Laroche ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Aspart ◽

Insulin Detemir ◽

Daily Administration ◽

Treat To Target ◽

Target Trial ◽

Mealtime Insulin ◽

Basal Bolus

Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial

Pediatric Diabetes ◽

10.1111/pedi.12724 ◽

2018 ◽

Vol 19 (7) ◽

pp. 1263-1270 ◽

Cited By ~ 2

Author(s):

Tadej Battelino ◽

Larry C. Deeb ◽

Magnus Ekelund ◽

Ona Kinduryte ◽

Georgeanna J. Klingensmith ◽

...

Keyword(s):

Type 1 Diabetes ◽

Randomized Trial ◽

Children And Adolescents ◽

Insulin Aspart ◽

Fixed Combination ◽

Insulin Degludec ◽

Efficacy And Safety

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2012-3249 ◽

2013 ◽

Vol 98 (3) ◽

pp. 1154-1162 ◽

Cited By ~ 133

Author(s):

Chantal Mathieu ◽

Priscilla Hollander ◽

Bresta Miranda-Palma ◽

John Cooper ◽

Edward Franek ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Target Trial ◽

Dosing Regimen ◽

Flexible Dosing

Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study

Journal of Diabetes Investigation ◽

10.1111/jdi.12748 ◽

2017 ◽

Vol 9 (3) ◽

pp. 567-572 ◽

Cited By ~ 2

Author(s):

Yoshio Nagai ◽

Ami Nishine ◽

Eriko Hashimoto ◽

Taiga Nakayama ◽

Yosuke Sasaki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Aspart ◽

Basal Insulin ◽

Japanese Patients ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily